Trials / Completed
CompletedNCT00916370
SPIRIT PRIME Clinical Trial
SPIRIT PRIME Clinical Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 525 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.
Conditions
- Myocardial Ischemia
- Coronary Artery Stenosis
- Coronary Disease
- Coronary Artery Disease
- Coronary Restenosis
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Core size Xience Prime | Core size includes a range of stent sizes. |
| DEVICE | Xience Prime Long Lesion (LL) | Long lesion stent sizes include a range of sizes. |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-03-01
- Completion
- 2014-02-01
- First posted
- 2009-06-09
- Last updated
- 2015-06-08
- Results posted
- 2012-06-01
Locations
62 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00916370. Inclusion in this directory is not an endorsement.